The past 17 years have been a time of significant progress in
the care of patients with Multiple Myeloma. Our Myeloma program
in Arkansas has developed innovations that have taken us
directly from research to the treatment of patients who
represent all age groups, nationalities and levels of disease.
The tremendous strides we have made in changing the outcome for Myeloma patients, stem from novel research and its applications,
including:
Combination chemotherapy using VAD (Vincristine,
Adriamycin, Dexamethasone)
Bone marrow and peripheral blood stem cell transplants
Tandem bone marrow transplants with increased remission
rates
Bone marrow transplants for patients over the age of 70
Transplants for patients with severe renal disease
Introduction of Thalidomide as a treatment for Myeloma
Cytogenetic research to identify chromosomal prognostic
factors
Genetic chip analysis at the cutting edge of genomic
science
The phenomenal growth of the Myeloma program at UAMS is
marked by distinct milestones:
More than 7,000 bone marrow transplants have been
performed
More than 7,400 new patients have come to Arkansas to be
treated for Myeloma
More than 200 peer-reviewed publications have gone to
press from the Myeloma clinical and research staff
More than 40 countries on six continents are represented
in our patient population
The team approach we use in treating Myeloma will be of great benefit to you. Our
physicians,
nurses
and other support
staff all work together to offer a comprehensive approach to
your care. Please read on throughout this website to learn
how our unique program can benefit you and your loved ones.
Having problems
with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for
Research and Therapy, University of Arkansas for Medical Sciences Terms and Conditions of Use
The information on the Myeloma Institute web site
is not intended as a substitute for professional medical attention. The
information is intended only as an aid in understanding current medical
knowledge. A physician should always be consulted for any health concern or
medical condition. The Myeloma Institute web site provides links to other
organizations as a service to our readers. The Myeloma Institute is not
responsible for the information provided on other web sites.